To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
To determine the optimal schedule for three-dimensional verification imaging and necessary re-planning of patients undergoing IMPT for a rapidly changing tumor (small cell lung cancer). * To determine the rate of cardiac toxicities from IMPT in patients with small cell lung cancer compared with historical controls receiving photon-based treatment. * To determine the rate of pneumonitis and esophagitis from IMPT and compare with historical controls receiving photon based treatment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
Winship Cancer Institute
Atlanta, Georgia, United States
RECRUITINGPatients with small cell lung cancer (SCLC) will be assessed with the intensity-modulated proton therapy (IMPT).
Patients enrolled will experience \<35% incidence of cardiac events at 1-year. Cardiac events included are acute heart disease, acute myocardial infarction, cardiomyopathy, dysrhythmia, heart failure, pericarditis, and pericardial effusion.
Time frame: Up to 1 year from study start
Determination of the optimal frequency of conebeam CT during treatment and subsequent need for adaptive re-planning
The optimal frequency of conebeam CT during treatment will be determined by a mixed model: * The local control, distant metastases, patterns of failure will be summarized as frequency and percentage. * Chi-square test will be used to test their relationships with other categorical variables. * General linear model will be used to measure their association with continuous covariates with and without adjusting for other factors
Time frame: Up to 1,2, and 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.